NEUROLOGIE PRO PRAXI / Neurol. praxi. 2023;24(4):286-292 / www.neurologiepropraxi.cz 292 PŘEHLEDOVÉ ČLÁNKY Novinky v léčbě myasthenia gravis One. 2022;17(6):e0269749. doi:10.1371/journal.pone.0269749. 7. Harris L, Allman PH, Sheffield R, Cutter G. Longitudinal Analysis of Disease Burden in Refractory and Nonrefractory Generalized Myasthenia Gravis in the United States. J Clin Neuromus‑ cul Dis. 2020;22(1).11-21. doi:10.1097/CND.0000000000000301. 8. Hewett K, Sanders DB, Grove RA, et al. Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. Neurology. 2018;90(16):e1425-e1434. doi:10.1212/WNL.0000000000005323. 9. Howard J, Bril V, Vu T, et al. Efficacy, Safety, and Tolerability of Efgartigimod in Patients With Generalized Myasthenia Gravis: Analysis of the Phase 3 ADAPT Study (4520). Neurolo‑ gy. 2021;96(15 Supplement). 10. Howard JF, Bresch S, Genge A, et al. Safety and Efficacy of Zilucoplan in Patients with Generalised Myasthenia Gravis (RAISE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study. The Lancet Neurology. 2023;22(5):395-406. https://doi.org/10.1016/S1474-4422(23)00080-7. 11. Howard JF, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody- -positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976-986. doi:10.1016/ S1474-4422(17)30369-1. 12. Jaretzki A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg. 2000;70(1):1623. doi:10.1212/wnl.55.1.16. 13. Lysák D. Imunoterapie pomocí CAR T-lymfocytů. Onko‑ logie. 2015;9(1):13-18. 14. Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: Clinical signposts and treatment strategies. Ther Adv Neurol Disord. 2018;11. doi:10.1177/1756285617749134. 15. McKeage K. Ravulizumab: First Global Approval. Drugs. 2019;79(3):347-352. doi:10.1007/s40265-019-01068-2. 16. Menon D, Barnett C, Bril V. Novel Treatments in Myasthenia Gravis. Front Neurol. 2020;11. doi:10.3389/fneur.2020.00538. 17. Menon D, Bril V. Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals. Drugs. 2022;82(8):865-887. doi:10.1007/s40265-022-01726-y. 18. Murai H, Uzawa A, Suzuki Y, et al. Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study. J Neurol Sci. 2019;407:116419. doi:10.1016/j.jns.2019.08.004. 19. Narayanaswami P, Sanders DB, Wolfe G, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology. 2021;96(3):114-122. doi:10.1212/ WNL.0000000000011124. 20. Ndegwa S, Mierzwinski-Urban M. Emerging Drugs for Generalized Myasthenia Gravis. Can J Heal Technol. 2022;2(2):114122. doi:10.51731/cjht.2022.270. 21. Nowak RJ, Coffey CS, Goldstein JM, et al. Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study. Neurology. 2022;98(4):e376-e389. doi:10.1212/WNL.0000000000013121. 22. Oh S, O’Connor K, Payne A. MuSK Chimeric Autoantibody Receptor (CAAR) T Cells for Antigen-specific Cellular Immunotherapy of Myasthenia Gravis (2769). Neurology. 2020;94(15 Supplement). 23. Sánchez-Tejerina D, Sotoca J, Llaurado A, et al. New Targeted Agents in Myasthenia Gravis and Future Therapeutic Strategies. J Clin Med. 2022;11(21):6394. doi:10.3390/jcm11216394. 24. Schneider-Gold C, Reinacher-Schick A, Ellrichmann G, Gold R. Bortezomib in severe MuSK-antibody positive myasthenia gravis: First clinical experience. Ther Adv Neurol Disord. 2017;10(10):339-341. doi:10.1177/1756285617721093. 25. SÚKL Státní ústav pro kontrolu léčiv [online]. Dostupné z: https://prehledy.sukl.cz/. 26. Tandan R, Hehir MK, Waheed W, Howard DB. Rituximab treatment of myasthenia gravis: A systematic review. Muscle and Nerve. 2017;56(2):185-196. doi:10.1002/mus.25597. 27. Tannemaat MR, Verschuuren JJGM. Emerging therapies for autoimmune myasthenia gravis: Towards treatment without corticosteroids. Neuromuscul Disord. 2020;30(2):111-119. doi:10.1016/j.nmd.2019.12.003. 28. Týblová M. Current and future therapeutic options for the treatment of the generalized form of myasthenia gravis. Ces a Slov Neurol a Neurochir. 2023;86(2):100-106. doi:10.48095/cccsnn2023100. 29. U.S. National Library of Medicine [online]. Dostupné z: https:// classic.clinicaltrials.gov/. 30. Ward ES, Gelinas D, Dreesen E, et al. Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune Disorders. Front Im‑ munol. 2022;13(June):1-13. doi:10.3389/fimmu.2022.892534. Řešením je ELEKTRONICKÉ PŘEDPLATNÉ Chcete číst aktuální články časopisu Neurologie pro praxi ON-LINE? ◼ na www.neurologiepropraxi.cz ČTĚTE IHNEDv podobě listovačky či ve formátu PDF ◼ bez přihlášení/předplatného jsou články přístupné až po 1 roce ◼ 6 čísel/rok – 1008 Kč (vč. tematických příloh) Objednávejte v našem e-shopu➜ www.solen.cz
RkJQdWJsaXNoZXIy NDA4Mjc=